SCHEMBL2597652

SCHEMBL2597652

COc1ccc2[nH]c3ccc(OC)cc3c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
KDM4E B2RXH2 4/20 1.00
HSD17B10 Q99714 3/20 1.00
MEN1 O00255 2/20 1.00
MAPT P10636 2/20 1.00
KMT2A Q03164 2/20 1.00
GFER P55789 2/20 1.00
TSHR P16473 1/20 1.00
HPGD P15428 4/20 0.81
ACHE P22303 4/20 0.70
CHUK O15111 1/20 0.68
BCHE P06276 2/20 0.66
ABCG2 Q9UNQ0 1/20 0.65
MTNR1A P48039 1/20 0.62
MTNR1B P49286 1/20 0.62
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
APOBEC3A P31941 1/20 0.56
APOBEC3G Q9HC16 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391519 1.00 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10MEN1MAPT
Glycozoline SCHEMBL11981403 0.90 ALDH1A1 (0.81) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL29562964 0.90 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL532262 0.90 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL29643258 0.90 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL29233384 0.88 HSD17B10 (0.78) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL6976263 0.88 ALDH1A1 (0.78) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL6983296 0.88 ALDH1A1 (0.78) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL1182043 0.88 ALDH1A1 (0.78) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL31188764 0.88 ALDH1A1 (0.78) ALDH1A1KDM4EHSD17B10MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283989-B Trans-quinacridone compound and preparation method and application thereof 华南理工大学 2024-03-01 CN claimed
EP-4025643-B1 THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT BASF SE (DE) 2023-08-16 EP claimed
US-20220315738-A1 THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT BASF SE (DE) 2022-10-06 US claimed
EP-4025643-A1 THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT BASF SE (DE) 2022-07-13 EP claimed
CN-114341266-A Heat-resistant thermoplastic moulding materials 巴斯夫欧洲公司 2022-04-12 CN claimed
WO-2021043859-A1 THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT BASF SE (DE) 2021-03-11 WO claimed
CN-109053680-B Organic small-molecule photoelectric functional material based on 3-benzoylpyridine as receptor unit, and preparation method and application thereof 华南理工大学 2020-07-28 CN claimed
CN-109053680-A It is the small organic molecule photoelectric functional material and its preparation method and application of receptor unit based on 3- benzoyl pyridine 华南理工大学 2018-12-21 CN claimed
CN-106674514-B A kind of polyarylether, preparation method and nano-carbon modified material and composite material of the main chain containing carbazole 吉林大学 2018-10-23 CN claimed
CN-108329253-A Preceding neurogenic compounds 得克萨斯州大学系统董事会 2018-07-27 CN claimed
CN-106674514-A Polyarylether with main chain containing carbazole, preparation method, nanocarbon modified material and composite 吉林大学 2017-05-17 CN claimed
CN-103415289-B Pro-neurogenic compounds 得克萨斯州大学系统董事会 2017-04-12 CN claimed
EP-4707281-A1 ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT Canon Kabushiki Kaisha (JP) 2026-03-11 EP disclosed
US-12565613-B2 Quantum dots with donor-acceptor ligands SHOEI CHEMICAL INC. (JP) 2026-03-03 US disclosed
US-20260059933-A1 ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT CANON KABUSHIKI KAISHA (JP) 2026-02-26 US disclosed
US-20250324899-A1 MANUFACTURING METHOD OF PEROVSKITE-TYPE SOLAR CELL TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2025-10-16 US disclosed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US disclosed
CN-102702074-A Sulfonyl chloride compound taking carbazole as fluorogen and preparation method and application thereof UNIV YANGZHOU 2012-10-03 CN disclosed
WO-2012049167-A1 NOVEL OLIGOTHIOPHENE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USES UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) 2012-04-19 WO disclosed
WO-2011145876-A2 NOVEL HYBRID ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME 주식회사 두산 (KR) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565613-B2 Quantum dots with donor-acceptor ligands HCCS, FDPS, FTH1 ALDH1A1 125/4885KDM4E 4066/4885HSD17B10 1106/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX ALDH1A1 1280/4885KDM4E 4210/4885HSD17B10 1113/4885
US-20260059933-A1 ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT SOD1, MSL1, APOL1 ALDH1A1 817/4885KDM4E 4228/4885HSD17B10 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.